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1  INTRODUCTION 
 
1.1  Human Immunodeficiency Virus (HIV) 
 
1.1.1  HIV/AIDS 
                                                                                   
                                                                                              
                                                                                        
                                                                                         
                                                                                    
                                                                                        
                                                                                            
                                                                                         
                                                                                            
                    
 
                                                                                         
                                                                                             
                                                                                            
                                                                                           
                                                                                             
                                                                                         
                                                                                             
                                                                                           
                                                                                           
                                                                                                       
                                                                                        
                                                                                           
                                                                                         
                                                                                            
                                                                                              
                                                                                           
                                                 
 
1.1.2  Taxonomy 
                                                                                           
                                                                                                              
 
     
                                                                                              
                                                                                           
                                                                                               
                                                                                           
                                                                                            
                                                                                    
 
                                                                                            
                                                                                           
                                                                                        
                                                                                            
                                                                                            
                                                                                       
                                                                                               
                                                         
 
1.1.3  Morphology 
                                                                                              
                                                                                         
                                                                                               
                                                                                      
                                                                                           
                                                                                          
                                                                                                
                                                                                              
                                                                                             
                                                                                          
                                                                                                
                                                                                             
                                                                                              
                                                                                               
                                                                                            
                                                                                        
                                                                                          
                                                                                           
                                                                                 
                                                                                                      
                                                                                               
                                                                                                       
 
     
                                                                                                
          
 
 
Figure 1. A mature HIV-1. The HIV is an enveloped virus containing the proteins gp120 and 
gp41  as  envelope  glycoproteins.  The  virus  has  a  genome  with  two  ssRNAs  which  are 
transcribed to cDNA via the viral reverse transcriptase. (Kendall 1999) 
 
1.1.4  Genome 
                                                                                        
                                                                                        
                                                                                          
                                                                                   
                                                                                                
                                                                                              
                                                                                                  
                                                                                         
                                                                                          
                                                                                              
                                                                                       
                                                                                          
                                                                                                     
                                      
 
     
 
Figure 2. The HIV-1 genome. (A) The integrated proviral genome, with an LTR flanking both 
sides.  (B)  The  viral  RNA  genome  with  the  5'  Cap  structure  and  the  3'  poly-A  sequence. 
(modified based on (Modrow et al. 2003)) 
 
                                                                                            
                                                                                           
                                                                                               
                                                 
 
1.1.5  Viral Proteins  
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1.1.6  Vif 
                                                                                             
                                                                                                   
                                                                                           
                                                                                          
                                                                                             
                                                                                                  
                                                                                          
                                                                                            
                                                                                    
                                                                                        
                                                                                                        
                                                                                              
                                                                                           
                                                                                             
                                                                                             
                                                                                           
                                                                                                  
                                                                                                  
                                                                                                   
 
     
                                                                                                
                                                                                                   
                                                                                                    
                                                                                         
                                                                                       
                                                                                            
                                      
 
1.1.7  Replication 
                                                                                               
                                                                                         
                                                                                       
                                                                                               
                                                                                           
                                                                                       
                                                                                     
                                                                            
 
                                                                                           
                                                                                           
                                                                                        
                                                                                            
                                                                                      
                                                                                             
                                                                                          
                                                                                           
                                                                                     
                                                                                         
                                                                                         
                                                                                        
                                                                    
 
     
   
Figure 3. HIV- reverse transcription reaction. The first step is the binding of the tRNA onto the 
5’  PB  region of the  RNA.  In  step  II  the  DNA  synthesis  begins, covering  the  PB,  U5  and  R 
regions of the 5’ end. In the third step, the primer jumps to the other side, and in the fourth 
step the DNA minus strand is elongated. In step V, the RNA of the hybrid is degraded with the 
RHase-H activity of the reverse transcriptase. In step VI the tRNA is removed. In step VII, the 
DNA forms a circle and the U3, R and U5 region of the 3’ end is synthesized. The primer then 
jumps to the other side in step VIII, and the plus strand DNA can be completed as shown in 
steps IX and X. (Fields et al. 2007) 
 
                                                                                           
                                                                                                   
                                                                                              
                                                                                           
                                                                                              
                                                                                               
                                                                                           
                                                                                                     
 
     
                                                                                                 
                                                                                                
                                                                                              
                                                                                      
                                               
 
                                                                                          
                                                                                                
                                                                                     
                                                                                         
                                                                                        
                                                                                      
 
1.2  The Immune System 
                                                                                               
                                                                                         
                                                                                        
                                                                                      
                                                                                              
                                                                                       
                                                                                              
                                        
 
                                                                                           
                                                                                               
                                                                                                 
                                                                                                   
                                                                                             
                                                                                                 
                                                                                      
                                                                                                
                                                                                              
                                                                                             
                                                                                                     
                                                                                         
                                                                                        
                                                                                                   
                                                     
 
                 
 
     
 
Figure 4. Classic scheme of haematopoiesis. The cells which make up the immune system all 
derive from one progenitor, the hematopoietic stem cell. http://www.omsusa.org/cellsis.jpg 
 
1.2.1  CD34+ Hematopoietic Stem Cells 
                                                                                                
                                                                                           
                                                                                             
                                                                                              
                                                                                                       
                                                                                         
                                                                                        
                                                                                                   
                                                                                            
                                                                                        
                                                                                               
                                                                                                      
                                                                                            
                                                                                           
                                              
 
1.2.2  Macrophages 
                                                                                                       
                                                                                                 
                                                                                   
                                                                                                         
 
     
                                                                                             
                                                                                             
                                                                                        
                                                                                       
                                                                                         
                                                                                      
                                                                                               
                                                                                          
                                                                                         
                                                                                                  
                                                                                  
 
 
Figure 5. Macrophages. Shown here is a picture of a macrophage taken under a transmission 
electron  microscope  (left)  and  one  while  using  a  scanning  electron  microscope  (right). 
Macrophages  are  specialized  antigen  presenting  cells  which  phagocytose  pathogens  and 
present their antigen via the MHCII molecule on their cell surface. (Janeway 2004) 
 
1.2.3  Dendritic Cells 
                                                                                          
                                                                                                      
                                                                                           
                                                                                                
                                                                                                 
                                                                                      
                                                                                               
                                                                                            
                                                                                          
                                                                                                  
                                                                                                    
                                                                                       
                                                                                                
                                                                                             
                                                                                                               
 
     
                                                                                    
                                                                                           
                                                                                           
                                                                                           
 
 
Figure 6. Dendritic cells. Shown here is a picture of a DC taken under a transmission electron 
microscope (left) and one while using a scanning electron microscope (right). Dendritic cells 
are  specialized  antigen  presenting  cells  and  have  the  highest  concentration  of  MHCII 
molecules on their cell surface. They present the antigens specifically to T cells activating the 
adaptive immunity. (Janeway 2004) 
 
1.2.4  Macrophages/Dendritic cells and HIV 
                                                                                       
                                                                                     
                                                                                              
                                                                                              
                                                                                       
                                                                                             
                                                                                       
                                                                                                
                                                                                              
                                                                                           
                                                                                                
                                                                                                   
                                                                                            
                                                                                         
                                                                                        
                     
                 
 
     
 
Figure 7. HIV-1 transmission. The transmission of HIV usually takes place over the mucosal 
membrane where it binds and infects dendritic cells and macrophages. It then infects CD4+ T 
cells in the sub-epithelial level. There is also the possibility that the DCs can capture virus 
without being infected via DC sign. This is then presented to CD4+ T cells which are in turn 
infected. After the infection enters the lymph nodes, the viral production increases and leads 
to  host  viremia  and  infection  of  the  gut  associated  lymphoid  tissue  (GALT).  (Piguet  and 
Steinman 2007) 
 
                                                                                                
                                                                                                
                                                                                          
                                                                                       
                                                                                       
                                                                                             
                                                                                               
                                                                                      
                                                                                             
                                                                                                
                                                                                              
                                                                                                   
                                                                                                          
 
     
                                                                                                 
      
 
 
Figure 8. Comparison of the HIV-1 infection in macrophages and T cells. There are many steps 
in the viral infection of the cells that differ in macrophages and T cells. Some of these include 
viral entry and entry into the nucleus. (Verani et al. 2005)  
 
1.2.5  Interferon alpha 
                                                                                                  
                                                                                                   
                                                                                         
                                                                                                          
                                                                                                
                                                                                         
                                                                                           
                                                                                                   
                                                                                                    
                                                                                                
                
                 
 
     
Table 1. Toll-Like Receptor Ligands. The TLRs which activate IFN-α/β are highlighted in red. 
(Takeda and Akira 2004; Beutler 2005; Sandor and Buc 2005; Zhang et al. 2007) 
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Figure 9. An overview of TLR signaling pathways leading to IFN-α/β activation. The activation 
of specific TLRs can in turn stimulate a MyD88- dependent or independent pathway causing 
the activation of IFN-α/β through NF-κB or an IRF protein. (modified based on (Edwards et al. 
2007; Zhang et al. 2007)) 
 
                                                                                                 
                                                                                         
                                                                                       
                                                                                     
                                                                                              
                                                                                             
                                                                                               
                                                                                                   
                                                                                                
                                                                                          
                                                                                      
                 
 
     
 
Figure 10. IFN signaling pathways. IFN-α plays a large role in the immune response to viral 
infections. The receptor is the type I interferon receptor and consists of two transmembrane 
subunits: IFNAR1 and IFNAR2 which induce the Stat signaling pathway. The activation of the 
Stat pathway turns on many genes containing specific activation signals such as GAS, ISRE or 
Stat. (Takaoka and Yanai 2006) 
 
                                                                                                  
                                                                                         
                                                                                       
                                                                                                 
                                                                                                    
                                                                                             
                                                                                          
                                                                                                     
                                                    
 
1.2.6  LPS  
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Figure  11.  Signaling  pathways  of  LPS  in  monocytes.  (A)  The  structure  of  LPS  (Guha  and 
Mackman 2001). (B) The signaling pathway for LPS requires TLR-4, CD14 and MD-2. LPS is 
bound by LBP in the serum and the LPS is then transferred to the cell surface protein CD14. It 
then interacts with the TLR-4, which activates various MAPK pathways and the IKK pathway 
via MyD88. (Guha and Mackman 2001) 
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1.2.7  APOBEC3G 
                                                                                         
                                                                                                  
                                                                                        
                                                                                           
                                                                                    
                                                                                  
                                                                                       
                                                                                        
                                                                      
 
 
                 
 
     
      
Figure 12. The proposed antiviral mechanism of APOBEC3G in HIV-1 infected cells. (A) The 
different APOBEC proteins and their conserved cytidine deaminase motifs, APOBEC3B, 3D/E, 
3F,  and  3G  all  have  2  cytidine  deaminase  motifs.  Under  the  diagram  of  the  genes  is  the 
chemical reaction for the cytidine deamination to uridine. (Holmes et al. 2007) (B) The left side 
shows  the  proposed  pathway  of  APOBEC3G  active  in  cells  infected  with  wt  HIV-1.  The 
APOBEC3G is led to the proteasome with help from the viral Vif protein and is degraded. The 
right picture depicts the APOBEC3G pathway when infected with HIV-1 lacking the Vif protein. 
The APOBEC3G protein is packaged into the virions and restricts the viral production in the 
target cells. This is done by 4 proposed ways: 1 – an unknown mechanism that blocked the 
formation  of  the  reverse  transcripts,  2  –  cytidine  deamination  of  the  ssDNA,  3  –  mutated 
reverse  transcripts  could  be  recognized  by  the  cellular  repair  pathways  because  of  the 
presence  of  uracil  and  degraded,  or  4  –  a  possible  recruiting  of  a  cellular  endonuclease 
causing the HIV-1 reverse transcripts to be degraded independent of editing. (Holmes et al. 
2007) 
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1.3  Goal 
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2  MATERIALS 
 
2.1  Chemicals  
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2.3  Antibodies 
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2.4  Kits 
Kit  Company 
                                               
                           
                                                      
                                      
        
                                 
                                  
                                    
                    
 
2.5  Plasmids 
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2.6  Primers and Oligonucleotides 
                                                                                             
                 
 
                                                 
 
HIV env Primers          5’￿ ￿ ￿ ￿ 3’ 
 
Env outer primers: 
                                  
                                  
 
Env inner primers: 
                                    
                                     
 
APOBEC3 Primers   5’￿ ￿ ￿ ￿ 3’ 
                                                
                                             
 
                                         
                                                      
 
         
 
                                              
                                                 
 
Normalization Primers    5’￿ ￿ ￿ ￿ 3’ 
                                           
                                          
 
                                              
                                                 
 
                                         
                                            
 
siRNA Oligonucleotides (target sequence is in bold)  5’￿ ￿ ￿ ￿ 3’ 
                     GC ATC GTG ACC AGG AGT AT            A TAC TCC 
TGG TCA CGA TGC               
                              G CAT CGT GAC CAG GAG TAT             
ATA CTC CTG GTC ACG ATG C     
 
                     AA GCA ACC AGG CTC CAC AT            A TGT GGA 
GCC TGG TTG CTT               
                              A AGC AAC CAG GCT CCA CAT             
ATG TGG AGC CTG GTT GCT T     
 
                     AA CCG CAT CTA TGA TGA TC            G ATC ATC 
ATA GAT GCG GTT              
                              A ACC GCA TCT ATG ATG ATC             
GAT CAT CAT AGA TGC GGT T     
 
                      CA ACC AGG CTC CAC ATA AA            T TTA TGT 
GGA GCC TGG TTG               
                               C AAC CAG GCT CCA CAT AAA             
TTT ATG TGG AGC CTG GTT G     
 
                      GC ATC GTG ACC AGG AGT AT            A TAC TCC 
TGG TCA CGA TGC              
                               G CAT CGT GAC CAG GAG TAT             
ATA CTC CTG GTC ACG ATG C     
              
 
         
                          TGG TCC ACA GGA CAC TCG T            AC GAG 
TGT CCT GTG GAC CA                  
                               T GGT CCA CAG GAC ACT CGT             
ACG AGT GTC CTG TGG ACC A             
 
                       AA CAT GTC ATG TGT CAC ATC T            AG ATG 
TGA CAC CTG ACA TGT T              
                               A  ACA TGT CAT GTG TCA CAT CT          
  A GAT GTG ACA CAT GAC ATG TT     
 
2.7  Cell Lines 
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2.8  Bacteria 
Name  Genotype  Company 
                    
                
 
                           
                          
                           
                            
           
 
2.9  Virus 
Virus Name  Properties  Reference 
                
 
                            
             
                  
                          
      
 
2.10 Medium Supplements and Buffers 
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2.11  Cell Culture and Bacteria Medium 
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2.12  Hardware and Other Supplies 
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3  METHODS 
 
3.1  Cell culture 
 
3.1.1  PBMC isolation 
                                                                                                 
                                                                                          
                                                                                           
                                                                                           
                                                                                             
                                                                                          
                                                                                         
                                                                                 
 
3.1.2  Macrophage differentiation from PBMCs  
                                                                                              
                                                                                   
                                                                                                   
                                                                                       
                                                                    
                     
    
                                                                                       
                                                                                        
                                                                                      
                                                                  
       
            
                                                                                      
               
 
3.1.3  Dendritic cell differentiation from PBMCs 
                                                                                             
                                                                                        
      
                                                                                         
                                                                                           
                                                                                          
                                                                                            
                                                                                             
                                                                                          
 
         
 
3.1.4  CD34+ Cultivation 
                                                                                         
                                                                                
                                                                                             
                                                                               
                                                                                      
                                                                                              
                                                                                          
                                                                                         
      
 
                                                                                            
                                                                                          
                          
                                                                      
                                                                                                    
                                          
                                                      
                  
 
3.1.5  Macrophage differentiation from CD34+ cells 
                                                                                        
                                                                                          
                                                                        
               
                                                                                       
                                                                                                 
                                                                                           
                                                                                         
                                                                                  
                                                                                           
                                              
 
3.1.6  Cultivation of cell lines 
                                                                                                
                                                                                     
                                                                                         
                                                                            
            
 
         
3.1.7  Splitting Adherent Cells 
                                                                                         
                                                                                         
                                                                                              
                                                                                      
                                                                                                
                    
 
3.1.8  Splitting Suspension Cells 
                                                                                         
                                                              
 
3.1.9  Freezing/Thawing Cells 
                                                                                               
                     
                                                                 
                                                                                             
                                                                                                 
 
                                                                                     
                                                                                          
                                                                                       
                                                                                          
                                         
 
3.2  FACS Analysis 
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3.3  Annexin-V Staining 
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3.4  Lentiviral Vectors (LVV) 
                                                                                                       
                                                                                                 
                                                                                          
                                                                                               
                                                                                                     
                                                                                       
                                                                                                       
                                                                                                
                                                                                           
                                                                                         
                                                                                           
                                                                                             
                                                                                              
                            
            
 
         
3.4.1  Lentiviral vector production 
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3.4.2  Concentrating lentiviral vectors 
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3.4.3  Titration of lentiviral vectors 
                                                                                                   
                       
                                                                         
                                                                                                     
                                                                                                  
                                                                                          
                                                                                            
                                                                                          
                                                                                           
                                                                                                     
 
         
      
     
      
     
                                 
  
 
Figure  13.  FACS  analysis  of  a  titration  with  LVVs.  For  this  analysis,  using  a  dilution  of 
1:100,000 13.8% of the cells were eGFP positive, meaning they were transduced with the LVV. 
Putting this into the formula it is: Titer = 13.8%/100 x 50,000 cells seeded x 100,000. Using this 
formula, the titer is 6.9x10
8 infectious particles /ml. 
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Figure 14. Determining the optimal MOI to transduce cell lines. In this case LVVs titered on 
Te671 cells were tested to determine the optimal MOI to use in HUT78 cells.  
      
                                            
                                        
                                    
 
         
3.4.4  Transduction 
                                                                                        
                                                                                            
                                                                                               
                                                                                       
      
 
3.5  Transfection 
 
3.5.1  Lipofectamin Transfection 
                                                                                              
                    
                                             
                                 
                                                                                                  
                                                                                     
                                                          
 
                                                                                              
                        
                                                               
                                                                                            
                                                                                         
                                                                                           
                                                                                         
                                                                                      
                                                                                       
                                                                                   
                                         
 
3.5.2  Calcium Phosphate Transfection 
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3.6  Titration of Viral Stocks 
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3.7  Stimulating and infecting cells 
                                                                                     
                                                                                       
                                                                                           
                                                                                            
                                                                                              
                                                                                 
     
                                                                                         
                                                                                        
                                                                                           
                                                                                                    
                                                           
 
                                                                                               
                                                                                           
                                                                                            
                                                                                           
                                                                                                         
 
         
                                                                                   
                                                                           
 
                                                                                                    
                                                                                                    
                                                                                           
                                                                                         
                                                                                    
                                                   
   
3.8  Infection of a Cell Line for Mutation Analysis 
                                                                                       
                                                 
                                            
                                                                                             
                                                                                         
                                                                                           
                                                                                                      
                                                                                              
                                                                                          
                                                                                             
                                                                                                      
                                                                                         
                                                                                        
                                                                                              
                                               
 
3.9  P24 ELISA Assay 
                                                                                            
                                                                                                   
                                                                                                   
 
                                   
                                                  
                                                                                      
                                                                                         
                                                                                        
                                                                                          
                                                                                             
                                                                                       
                                                                                                      
 
         
                                                                                       
                                                                                         
                                                                                                 
                                                                                            
                                                                                           
                                                                                         
                                                                                           
                                                                                        
                                                                                         
                                                                                          
                                                                                          
                                                                                           
                                                                                           
                                                                                     
                                                                                    
                                                                                                 
                                                                                        
                                                        
 
3.10  RNA Isolation  
                                                                                         
                                                                                                  
                                                                                         
                                            
                                            
                                                                                                
                                                                                                 
                                                                                      
                                                                                        
                                                                                          
                                                                                         
                                                                                      
                                                                                         
                                                                                         
                                                                                          
                                                                                        
                                                                                             
                                                                                          
                                                                                       
                                                                                           
                                                                                                        
 
         
                                                                                         
                                                                                    
 
3.11  Protein Isolation 
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3.12  Western Blot analysis 
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3.13  PCR 
                                                                                      
                                                                                      
                                                                                         
                                                                                       
                                                                                              
                                                                                     
                                                                                          
                                                                                          
                                                                                       
              
 
3.13.1  Reverse Transcription Assay (RT-PCR) 
                                                                                 
                                                                                         
                                                                                         
                                                                                          
                                                                                       
                                                                                            
                                                                                     
                                                                                         
                                                                                       
                                                                                                 
                                                                                         
                                                                                                     
 
         
                                                                                                 
                   
 
3.13.2  Real Time Quantitative PCR (RTq-PCR) 
                                                                                        
                                                                                          
                                                                                         
                                                                                          
                                                                                      
                                                                                   
                                                                                     
                                                                                              
                                                                                
                                                                                    
                                                                                  
                                                                                         
                                                                                               
                                                                                                     
                                                                                           
                                                                                            
                                                                                         
                                                                                         
                                                                                        
                                                                                            
                                                                                          
                                                                                           
                                      
 
                                                                                        
                                                                                         
                                                                                         
                                                         
 
                                                                                        
                                                                                           
                                                                                                    
                                                                                       
                                                            
             
 
         
 
Figure 15. PCR amplification versus cycle number. The horizontal orange line represents the 
threshold  where  the  amount  of  fluorescence  measured  is  substantially  higher  than  the 
background. In this case cDNA from cells producing different amounts of APOBEC3G was use 
with APOBEC3G primers. The line furthest to the left has the highest APOBEC3G production. 
The  curve  on  the  right  had  the  lowest  expression  of  APOBEC3G  mRNA  and  the  negative 
control did not go above the threshold. 
  
 
Figure 16. Melt Temperature curve. This is the melt curve from the experiment shown in figure 
15. It shows the PCR products which were amplified. If other peaks are present, it means that 
there are contaminations or the primer was bound unspecifically. 
 
3.13.3  Nested env PCR Amplification 
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3.14  DNA purification 
                                                                                    
                                                                                          
                                                                                       
                                                                                                   
                                                                                                
                                                                                    
                                                                                   
                                                                                          
                                                                                                 
                                                                                         
                                                                                          
                                                                                        
                                                                                          
                                                                                            
                                                                                            
                                                                                              
 
         
                                                                                         
                                                      
 
3.15  PCR Product Purification 
                                                                                           
                                                                                       
                                                                                               
                                                                                           
                                                                                           
                                                                                              
                                                                                       
                                                                                          
                                                                                                     
                                  
 
3.16  Digestion of DNA with Restriction Enzymes 
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3.17  Ligation  
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3.18  TA Cloning 
                                                                                        
                                                                                        
                                                                                                             
 
         
                                                                                              
                                                                                               
                                                                                           
                                                                                               
                                                                                                
                        
 
                                                                                              
                                                                                                 
                                                                                          
                                                                                           
                                                                                             
                                                                                                
                              
 
3.19  Transformation into E. coli Bacteria 
                                
                                                          
                                                                                            
                                                                                             
                                                                                            
                                                                                       
                                                                                                
                       
 
                                                                                              
                                                                                         
                                                                                       
                                                                                             
                                                                                                
                                                                                          
                                                                       
 
3.20  Preparation of Plasmid DNA (mini) 
                                                                                            
                                                                                                
                                                                                             
                                                                                             
                                                                                         
                                                                                                       
 
         
                                                                                          
                                                                                          
                                                                                                  
                                                                                         
                                                                                       
                                                                                          
                                                                                      
                                                                                         
                                                                                       
 
3.21  Preparation of Plasmid DNA (maxi) 
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3.22  Sequencing 
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3.23  Mann-Whitney U test statistic 
                                                                                        
                                                                                            
                                                                                                   
                                                                                               
                                                                                         
                                                                                            
                                                                                             
                                                                                                  
                                                                                                         
                                                                                                         
                                     
 
         
4  RESULTS 
 
4.1  APOBEC3G  is  upregulated  in  macrophages  stimulated  with 
IFN-α or LPS 
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Figure  17.  Expression  of  A3G  in  AB  Macrophages.  Macrophages  were  isolated  and 
differentiated from 5 different blood donors. The cells were then stimulated with either IFN-α or 
LPS and the expression of APOBEC3G was measured using RTq-PCR. (A) The expression of 
APOBEC3G in 4 of 5 blood donors increased up to six-fold after 24 hrs of stimulation with IFN-
α. (B) The expression of APOBEC3G in the macrophages from 2 of the blood donors increased 
with increasing IFN-α concentration. 
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4.2  The stimulated form of APOBEC3G is active 
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Figure 18. Transition mutations in the HIV Genome. The percentage of transition mutations 
found in the HIV-1 genome produced in macrophages of 3 different blood donors varied with 
donor, type of stimulant, and virus. (A) The HIV-1(AD8) viruses did not have as many mutated 
clones as the (B) HIV-1 (AD8)dVif viruses.  
 
4.3  Monocyte  differentiation  has  an  effect  on  the  APOBEC3G 
expression 
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Figure 19. Differentiation of monocytes. Monocytes from one blood donor were differentiated 
in 5 different ways to macrophages and to DCs. The cells were stained with differentiation 
markers and analyzed by FACS. All three macrophages had a high expression of CD14 and 
CD64  on  the  cell  surface;  however  the  phenotype  was  a  little  different.  The  macrophages 
differentiated with M-CSF were more round and those differentiated with GM-CSF were more 
elongated. The dendritic cells were in suspension and had dendritic arms which were more 
pronounced when matured. 
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Figure 20. The expression of APOBEC3G in monocytes derived macrophages and DCs. (A) 
RTq-PCR of APOBEC3G normalized with the EF1 protein in the different cell types shows the 
highest expression of APOBEC3G in the GM-CSF macrophages. (B) Western blot analysis of 
the  GM-CSF  macrophages  stimulated  with  IFN-α  or  LPS  and  stained  with  a  APOBEC3G 
antibody showed a clear upregulation of the protein after stimulation. (C) The Western blot 
analysis  of  the  AB  macrophages  (left)  and  the  immature  DCs  (left)  showed  much  less 
APOBEC3G protein than in the GM-CSF macrophages. 
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Figure 21. The course of infection in AB macrophages vs. GM-CSF macrophages. The viral 
infection of the AB and GM-CSF macrophages was followed with p24 antigen tests at different 
time points in the infection. (A) The infection in AB macrophages with either HIV-1 (ADA8) or 
HIV-1  (ADA8)dVif  and  stimulated  with  IFN-α  or  LPS.  (B)  The  viral  infection  in  GM-CSF 
macrophages  where  the  reduction  in  viral  production  in  the  stimulated  cells  was  more 
pronounced than in the AB macrophages. 
 
4.4  Direct regulation of APOBEC3G in macrophages. 
                                                                                         
                                                                                                  
                                                                                        
                                                                                          
                                                                                        
                                                                                    
                                
 
4.4.1  Transduction of macrophages 
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Figure 22. Macrophages transduced with eGFP LLVs. The transduction of macrophages from 3 
donors with  lentiviral  vectors containing eGFP at  increasing  MOIs  showed a  very  different 
transduction efficiency for each donor.  
 
4.4.2  Packaging of APOBEC3G 
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Figure  23.  Transduction  of  Te671  cells  with  APOBEC3G  LVVs.  FACS  analysis  of  LVVs 
containing APOBEC3G packaged in HEK 293T cells (A) without the Vif protein or (B) with the 
addition of the Vif protein and used to transduce Te671 cells. The addition of the Vif protein in 
the packaging cell line increased the viral titer 700-fold.  
 
4.4.3  Transduction of APOBEC3G LVVs 
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Figure 24. Expression of exogenous APOBEC3G. The cell lines, HEK 293T and HeLa were used 
to test the APOBEC3G LVVs. The cells were transduced with the vectors and then lysed. A. 
The RTq-PCR from the cell lines showing the increase in APOBEC3G mRNA. B. The Western 
blot was stained with the A3G C17 antibody, stripped and stained a second time with a GAPDH 
antibody as load control. The increase in the APOBEC3G protein is very clear. 
 
                                                                                        
                                                                                           
                                                                                         
                                                                                                
                                                                                         
                                                                                           
                                                                                            
                                                                                   
                                                                                         
                     
 
  Annexin-V 
                                     
                                           
Table  2.  Annexin-V  expression.  The  percentage  of  macrophages  expressing  Annexin-V  on 
their surface after transduction with lentiviral vectors containing either APOBEC3G or eGFP as 
determined by FACS analysis. The amount of Annexin-V was higher on the cells transduced 
with vectors containing APOBEC3G. 
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4.4.4  Downregulation of APOBEC3G via LVV containing shRNA 
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Figure 25. APOBEC3G expression in 293T cells transduced with shRNA. HEK-293T cells were 
transduced  with  APOBEC3G  LVVs  followed  by  LVVs  containing  shRNAs  either  against 
APOBEC3G or a scramble shRNA. 
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Figure 26. Expression of APOBEC3G in cells containing shRNA. (A) The percent APOBEC3G 
mRNA expression in HEK 293T and HeLa cells transduced with LVVs containing APOBEC3G 
followed by shRNA against APOBEC3G or a scramble sequence as determined by RT qPCR. 
(B) The Western blot showing the protein expression of the cells used to test the shRNA LVVs. 
The  blot  from  the  HEK-293T  cells  was  quantified  relative  to  GAPDH  and  showed  that  the 
shRNA caused an 84% decrease in A3G protein.  
 
4.5  The  effect  of  direct  APOBEC3G  regulation  on  the  HIV-1 
infection of TZM-bl cells. 
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Figure 27. The expression of A3G and the infection in transduced TZM-bl cells. (A) The mRNA 
expression of APOBEC3G after transduction of the cells. The expression from the APOBEC3G 
LVVs  was  reduced  in  the  cotransduction  with  shRNA  against  APOBEC3G.  (B)  The  p24 
expression in the TZM-bl cells infected with dVif HIV-1. The downregulation of the infection by 
A3G was rescued by the cotransduction with a LVV containing shRNA against APOBEC3G. 
 
4.6  CD34+ Cells 
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4.6.1  Differentiation of CD34+ cells into macrophages 
                                                                                               
                                                                                              
                                                                                             
                                                                                               
                                                                                       
                                                                                            
                                                                                                 
                                                                                             
                                           
 
 
Figure 28. Differentiation of CD34+ cells into Macrophages. (A) The CD34+ cells after 1 week of 
culture. (B) The CD34+ derived macrophages after being differentiated. 
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Table  3.  Characterization  of  CD34+  cells  differentiation  to  macrophages.  The  results  from 
FACS analysis at different stages of CD34+ cell cultivation and differentiation showed a high 
amount of CD34 surface protein at the beginning which decreased to under 2% after being 
differentiated.   
 
4.6.2  Transduction of CD34+ Cells 
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Figure  29.  The  percentage  expression  of  eGFP  in  CD34+  cells  transduced  with  LVVs 
containing eGFP over time. The amount of positive cells drops rapidly in each of the donors. 
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Figure 30. The expression of APOBEC3G mRNA in CD34+ cells after 24 hours of stimulation. 
The CD34+ cells showed an increase in APOBEC3G expression in IFN-α stimulated cells. The 
cells  transduced  with  A3G-eGFP  lentiviral  vectors  also  showed  a  very  high  increase  in 
APOBEC3G. The shRNA did not have any major effect on the expression. 
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Figure 31. The expression of APOBEC3G mRNA in CD34 derived macrophages after 24 hrs of 
stimulation. The CD34+ derived Macs showed an increase in APOBEC3G expression in IFN-α 
stimulated cells. The cells transduced with A3G-eGFP lentiviral vectors also showed a very 
high increase in APOBEC3G. As in the CD34+ cells, the shRNA did not have any major effect 
on the expression of APOBEC3G. 
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4.6.3  Is IFN-α upregulated in the LVV transduced cells? 
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Figure  32.  The  expression  of  the  IFN-α  regulated  protein  OAS1  in  CD34+  cells.  The  cells 
transduced with the siScam1 sequence in donor #1 had an increase in OAS1 protein, which is 
an indication for IFN-α stimulation. The cells from the other 2 donors were transduced with a 
different scramble shRNA sequence (siScram2).  
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Figure 33. The expression of the IFN-α regulated protein OAS1 in CD34 derived macrophages. 
As  in  the  CD34+  cells,  the  macrophages  transduced  with  the  scramble  shRNA  (siScram1) 
sequence  in  donor  #1  had  an  increase  in  OAS1  protein,  which  is  an  indication  for  IFN-α 
stimulation. The new scramble sequence (siSram2) used in the other 2 donors did not show 
this effect. 
 
4.6.4  The expression of APOBEC3F 
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Figure 34. The expression of APOBEC3F in CD34+ cells. The expression of the A3F mRNA was 
upregulated in the IFN-α stimulated cells; however the LVVs had no noticeable affect on this 
protein. 
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Figure 35. The expression of APOBEC3F in CD34 derived macrophages. The expression of the 
A3F protein was upregulated after stimulation with IFN-α. However there was no effect from 
the LVVs transduced into the cells. This shows that the LVVs were specific for their target. 
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4.6.5  Infection of the CD34+ cells 
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Figure 36. Infection of CD34+ cells. This is a representative example of the p24 expression in 
CD34+  cells  infected  with  either  (A)  HIV-1  (AD8)  or  (B)  HIV-1  (AD8)  dVif  virus.  The  cells 
stimulated with IFN-α showed no active infection.  
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Figure  37.  The  p24  amount  in  the  supernatant  of  infected  CD34+ cells.  The  results from 3 
different  donors  transduced  with  4  different  vectors  and  infected  with  either  HIV-1  (ADA8) 
(right) or HIV-1 (ADA8) dVif virus (left). 
 
4.6.6  Infection of the CD34 derived macrophages 
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Figure 38. Infection of CD34 derived macrophages. This is a representative example of the p24 
expression  in  CD34  derived  macrophages  infected with  either (A)  HIV-1  (AD8) or  (B)  HIV-1 
(AD8) dVif virus. The cells stimulated with IFN-α or LPS showed no active infection and unlike 
in the CD34+ cells, the infectivity in the HIV-1(AD8) dVif virus was also reduced.  
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Figure 39.  The p24 amount in the supernatant of infected CD34 derived macrophages. The 
results from 3 different donors transduced with 4 different vectors and infected with either 
HIV-1 (ADA8) (right) or HIV-1 (ADA8) dVif virus (left). 
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5  DISCUSSION  
                                                                                         
                                                                                            
                                                                                             
                                                                                              
                                                                
 
5.1  APOBEC3G in monocyte derived macrophages 
                                                                                         
                                                                                       
                                                                                                 
                                                                                            
                                                                                        
                                                                                         
                                                                                             
                                                                                             
                                                                                            
                                                                                                 
                                                                                              
                                                                                 
                                                                                     
                                                                                                 
                                                                                         
                                                                                                         
                                                                                        
                                                                                           
                                                                                        
                                                                                               
                                                                                       
                                 
 
                                                                                  
                                                                                       
                                                                                    
                                                                                       
                                                                                             
                                                                                            
                                                                                          
                                                                                                         
 
         
                                                                                    
                                                                                                      
                                                                                            
                                                                                           
                                                                                                 
                                                                                    
                                                                                                
                                                                                      
                                                                                              
                                                                                               
                                                                                               
                                  
 
                                                                                            
                                                                                             
                                                                                        
                                                                                                 
                                                                                                
                                        
       
       
           
                      
                                                                                
       
   
    
           
                                                                        
                                                                                     
                                                                                           
                                                                                                
                                                                                  
                                                                                       
                                                                                    
                                                                                     
                                                                                     
                                                                                           
                                                                                                
                                                                                    
                                                                                       
                                
 
5.2  Direct regulation of APOBEC3G in cells 
                                                                                            
                                                                                        
                                                                                        
                                                                                                                
 
         
                                                                                          
                                                                        
                     
                                                                                          
                                                                                             
                                                                                   
                                                                                            
                                                                                                    
                                                                                          
                                                                                        
                                                                                              
                                                                                                     
                                                                                                
                                                                                            
                                                                                                  
                                                                                                
                                                                                                       
                                                                                              
                                                                                        
                                                                                                         
                                                                                                  
                                                                                           
               
 
                                                                                
                                                                                                
                                                                                           
                                                                                          
                                                                                       
                                                                                      
                                                                                           
                                                                                 
                                                                                               
                                                                                          
                                   
 
                                                                                     
                                                                                        
                                                                                                     
                                                                                            
                                                                                           
                                                                                                
 
         
                                                                                          
                                                                                      
                                                                                           
                                                                                    
                                                                                          
                                                                                             
                                                                                           
                                 
 
                                                                                    
                                                                                                   
                                                                                             
                                                                                     
                                                                                               
                                                                                       
                                                                                        
                                                                                     
                                                                                 
                                                                                         
                                                                                     
                                                                                    
                                                                                            
                              
 
5.3  APOBEC3G in CD34 cells 
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7.2  Plasmid Maps 
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7.3  P24 amounts during Infection 
7.3.1  CD34+ cells 
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Figure 40.  Infection of CD34+ cells from donor #1. The p24 expression in transfected CD34+ 
cells from donor #1 infected with either (A) HIV-1 (AD8) or (B) HIV-1 (AD8) dVif virus.              
 
          
7.3.1.2 Donor #2 
0 5 10 15
0
50000
100000
150000
200000
250000
            
         
   
days
p
2
4
 
[
p
g
/
m
l
]
0 5 10 15
0
50000
100000
150000
200000
250000
            
         
   
days
p
2
4
 
[
p
g
/
m
l
]
0 5 10 15
0
50000
100000
150000
200000
250000
            
         
   
days
p
2
4
 
[
p
g
/
m
l
]
0 5 10 15
0
50000
100000
150000
200000
250000
            
         
   
days
p
2
4
 
[
p
g
/
m
l
]
0 5 10 15
0
50000
100000
150000
200000
250000
            
         
   
days
p
2
4
 
[
p
g
/
m
l
]
0 5 10 15
0
50000
100000
150000
200000
250000
            
         
   
days
p
2
4
 
[
p
g
/
m
l
]
0 5 10 15
0
50000
100000
150000
200000
250000
            
         
   
days
p
2
4
 
[
p
g
/
m
l
]
0 5 10 15
0
50000
100000
150000
200000
250000
            
         
   
days
p
2
4
 
[
p
g
/
m
l
]
0 5 10 15
0
50000
100000
150000
200000
250000
            
         
   
days
p
2
4
 
[
p
g
/
m
l
]
0 5 10 15
0
50000
100000
150000
200000
250000
            
         
   
days
p
2
4
 
[
p
g
/
m
l
]
HIV-1 (AD8) HIV-1 (AD8)dVif
u
n
t
r
a
n
s
d
u
c
e
d
S
c
r
a
m
b
l
e
 
s
h
R
N
A
A
3
G
 
s
h
R
N
A
e
G
F
P
A
P
O
B
E
C
3
G
A B
Figure 41. Infection of CD34+ cells from donor #2. The p24 expression in transfected CD34+ 
cells from donor #2 infected with either (A) HIV-1 (AD8) or (B) HIV-1 (AD8) dVif virus.  
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Figure 42. Infection of CD34+ cells from donor #3. The p24 expression in transfected CD34+ 
cells from donor #3 infected with either (A) HIV-1 (AD8) or (B) HIV-1 (AD8) dVif virus.  
              
 
          
7.3.2  CD34 derived macrophages 
7.3.2.1 Donor#1 
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Figure  43.  Infection of  CD34+  derived  macrophages  from  donor  #1.  The  p24  expression  in 
transfected CD34+ cells from donor #1 infected with either (A) HIV-1 (AD8) or (B) HIV-1 (AD8) 
dVif virus.               
 
          
7.3.2.2 Donor #2 
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Figure  44.  Infection of  CD34+  derived  macrophages  from  donor  #2.  The  p24  expression  in 
transfected CD34+ cells from donor #2 infected with either (A) HIV-1 (AD8) or (B) HIV-1 (AD8) 
dVif virus.  
              
 
          
7.3.2.3 Donor #3 
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Figure 45. Infection of CD34+ derived macrophages from donor #3. The p24 expression in 
transfected CD34+ cells from donor #3 infected with either (A) HIV-1 (AD8) or (B) HIV-1 (AD8) 
dVif virus.  
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